Literature DB >> 31953663

Can radiomics improve the prediction of metastatic relapse of myxoid/round cell liposarcomas?

Amandine Crombé1,2,3,4, François Le Loarer5,6, Maxime Sitbon7, Antoine Italiano8, Eberhard Stoeckle9, Xavier Buy7, Michèle Kind7.   

Abstract

OBJECTIVE: The strongest adverse prognostic factor in myxoid/round cell liposarcomas (MRC-LPS) is the presence of a round cell component above 5% within the tumor bulk. Its identification is underestimated on biopsies and in the neoadjuvant setting. The aim was to improve the prediction of patients' prognosis through a radiomics approach.
METHODS: Thirty-five out of 89 patients with MRC-LPS managed at our sarcoma reference center from 2008 to 2017 were included in this IRB-approved retrospective study as they presented with a pre-treatment contrast-enhanced MRI (median age, 49 years old). Two radiologists reported usual conventional/semantic radiological variables. After signal intensity (SI) normalization, voxel size standardization of T2-WI, and whole tumor volume segmentation, 44 3D-radiomics features were extracted. Using least absolute shrinkage and selection operator penalized Cox regression on prefiltered features, a radiomics score based on 3 weighted radiomics features was generated. Four prognostic multivariate models for MRFS were compared using concordance index: (1) clinical model, (2) semantic radiological model, (3) radiomics model, and (4) radiomics + semantic radiological model.
RESULTS: Twelve patients showed a metastatic relapse. The radiomics score included FOS_Skewness, GLRLM_LRHGE, and SHAPE_Volume and correlated with MRFS (hazard ratio = 19.37, p = 0.0009) and visual heterogeneity on T2-WI (p < 0.0001). A high score indicated a poorer prognosis. After adjustment, the best predictive performances were obtained with model (4) (concordance index = 0.937) and the lowest with model (1) (concordance index = 0.637).
CONCLUSION: Adding selected radiomics features that quantify tumor heterogeneity and shape at baseline to a conventional radiological analysis improves prediction of MRC-LPS patients' prognosis. KEY POINTS: • Fourteen radiomics features quantifying shape and heterogeneity of myxoid/round cell liposarcomas on T2-WI were associated with metastatic relapse in univariate analysis. • A radiomics score based on 3 selected and weighted radiomics features was a strong and independent prognostic factor for metastatic relapse-free survival. • The best prediction of metastatic relapse-free survival for myxoid/round cell liposarcomas was achieved by combining the radiomics score to relevant radiological features.

Entities:  

Keywords:  Liposarcomas, myxoid; Magnetic resonance imaging; Patient-specific modeling; Prognosis; Sarcoma

Mesh:

Year:  2020        PMID: 31953663     DOI: 10.1007/s00330-019-06562-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  36 in total

1.  Soft-Tissue Sarcomas: Assessment of MRI Features Correlating with Histologic Grade and Patient Outcome.

Authors:  Amandine Crombé; Pierre-Jean Marcellin; Xavier Buy; Eberhard Stoeckle; Véronique Brouste; Antoine Italiano; François Le Loarer; Michèle Kind
Journal:  Radiology       Date:  2019-04-09       Impact factor: 11.105

2.  Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.

Authors:  C R Antonescu; S J Tschernyavsky; R Decuseara; D H Leung; J M Woodruff; M F Brennan; J A Bridge; J R Neff; J R Goldblum; M Ladanyi
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  survcomp: an R/Bioconductor package for performance assessment and comparison of survival models.

Authors:  Markus S Schröder; Aedín C Culhane; John Quackenbush; Benjamin Haibe-Kains
Journal:  Bioinformatics       Date:  2011-09-07       Impact factor: 6.937

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

5.  Quantification of fat content in lipid-rich myxoid liposarcomas with MRI: a single-center experience with survival analysis.

Authors:  Gokhan Kuyumcu; Brian P Rubin; Jennifer Bullen; Hakan Ilaslan
Journal:  Skeletal Radiol       Date:  2018-06-08       Impact factor: 2.199

6.  Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index.

Authors:  Ji Hyun Lee; Young Cheol Yoon; Sung Wook Seo; Yoon-La Choi; Hyun Su Kim
Journal:  Eur Radiol       Date:  2019-10-18       Impact factor: 5.315

7.  Soft-tissue myxomatous lesions: review of salient imaging features with pathologic comparison.

Authors:  Jonelle M Petscavage-Thomas; Eric A Walker; Chika I Logie; Loren E Clarke; Dennis M Duryea; Mark D Murphey
Journal:  Radiographics       Date:  2014 Jul-Aug       Impact factor: 5.333

8.  Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.

Authors:  Marco Fiore; Federica Grosso; Salvatore Lo Vullo; Elisabetta Pennacchioli; Silvia Stacchiotti; Andrea Ferrari; Paola Collini; Laura Lozza; Luigi Mariani; Paolo G Casali; Alessandro Gronchi
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

9.  Liposarcoma: outcome based on the Scandinavian Sarcoma Group register.

Authors:  Katarina Engström; Peter Bergh; Pelle Gustafson; Ragnar Hultborn; Helena Johansson; Rickard Löfvenberg; Olga Zaikova; Clement Trovik; Ola Wahlström; Henrik C F Bauer
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Metastatic pattern, local relapse, and survival of patients with myxoid liposarcoma: a retrospective study of 45 patients.

Authors:  Hanna M Fuglø; Katja Maretty-Nielsen; Dorrit Hovgaard; Johnny Ø Keller; Akmal A Safwat; Michael M Petersen
Journal:  Sarcoma       Date:  2013-06-20
View more
  6 in total

Review 1.  Magnetic resonance imaging of soft tissue sarcoma: features related to prognosis.

Authors:  Giulia Scalas; Anna Parmeggiani; Claudia Martella; Gianmarco Tuzzato; Giuseppe Bianchi; Giancarlo Facchini; Roberta Clinca; Paolo Spinnato
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-05-29

2.  Whole-tumor 3D volumetric MRI-based radiomics approach for distinguishing between benign and malignant soft tissue tumors.

Authors:  Brandon K K Fields; Natalie L Demirjian; Darryl H Hwang; Bino A Varghese; Steven Y Cen; Xiaomeng Lei; Bhushan Desai; Vinay Duddalwar; George R Matcuk
Journal:  Eur Radiol       Date:  2021-04-23       Impact factor: 5.315

Review 3.  Magnetic resonance imaging of trunk and extremity myxoid liposarcoma: diagnosis, staging, and response to treatment.

Authors:  Asif Saifuddin; Vanghelita Andrei; Ramanan Rajakulasingam; Ines Oliveira; Beatrice Seddon
Journal:  Skeletal Radiol       Date:  2021-04-01       Impact factor: 2.199

4.  Manual versus semiautomatic segmentation of soft-tissue sarcomas on magnetic resonance imaging: evaluation of similarity and comparison of segmentation times.

Authors:  Fernando Carrasco Ferreira Dionisio; Larissa Santos Oliveira; Mateus de Andrade Hernandes; Edgard Eduard Engel; Paulo Mazzoncini de Azevedo-Marques; Marcello Henrique Nogueira-Barbosa
Journal:  Radiol Bras       Date:  2021 May-Jun

5.  CT and MRI radiomics of bone and soft-tissue sarcomas: a systematic review of reproducibility and validation strategies.

Authors:  Salvatore Gitto; Renato Cuocolo; Domenico Albano; Francesco Morelli; Lorenzo Carlo Pescatori; Carmelo Messina; Massimo Imbriaco; Luca Maria Sconfienza
Journal:  Insights Imaging       Date:  2021-06-02

Review 6.  Radiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications.

Authors:  Damiano Caruso; Michela Polici; Marta Zerunian; Francesco Pucciarelli; Gisella Guido; Tiziano Polidori; Federica Landolfi; Matteo Nicolai; Elena Lucertini; Mariarita Tarallo; Benedetta Bracci; Ilaria Nacci; Carlotta Rucci; Marwen Eid; Elsa Iannicelli; Andrea Laghi
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.